SAR39459 alone or in combination with cemiplimab in adults with advanced solid tumors - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn more about the possible risks of the study drug (SAR439459) given alone or in combination with cemiplimab. We are also want to see how well the study drug works.
Colorectal Cancer, Hepatocellular Carcinoma (HCC), Urothelial Cancer, and Melanoma
Who Can Participate in the Study?
Adults, 18+ who:
- Have been diagnosed with advanced unresectable or metastatic melanoma (excluding uveal melanoma), colorectal cancer, urothelial cancer, or hepatocellular carcinoma
- Are willing to have a fresh biopsy of their tumor
- Do not have HIV, uncontrolled Hepatitis B, or untreated current Hepatitis C
What is Involved?
If you choose to join this study you will:
-Go through a screening period which will last about 4 weeks
-Have physical exams
-Have lab tests and other screening tests to see if you qualify for the study
If you’re able to join, you will:
-Get the study drug (SAR439459) by itself or in combination with cemiplimab once every 3 weeks via an intravenous (into the vein) infusion
-Have physical exams, lab tests, and other tests done throughout the study